- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Fairhope, Alabama • Covina, California + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer-Associated Thrombosis (CAT)
- Interventions
- REGN7508, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
- Conditions
- Venous Thromboembolism
- Interventions
- REGN9933, REGN7508, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Apixaban, Enoxaparin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more
- Conditions
- Peripheral Artery Disease (PAD)
- Interventions
- REGN7508, REGN9933, Placebo, Rivaroxaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 21
- States / cities
- Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 18 more
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Hialeah, Florida • New York, New York • El Paso, Texas
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, Apixaban, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 44
- States / cities
- Alexander City, Alabama • Dothan, Alabama • Fairhope, Alabama + 39 more
- Conditions
- Symptomatic Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Acetylsalicylic Acid (ASA), Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 36
- States / cities
- La Mesa, California • Rancho Mirage, California • Riverside, California + 28 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Glendale, Arizona • Little Rock, Arkansas + 37 more